^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    cusatuzumab (ARGX-110)

    i
    Other names: ARGX-110, ARGX 110, JNJ‑74494550, JNJ-4550, OV-1001
    Company:
    OncoVerity, argenx
    Drug class:
    CD70 inhibitor
    Related drugs:
    10d
    CULMINATE: A Study of Cusatuzumab Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive Chemotherapy (clinicaltrials.gov)
    P2, N=103, Active, not recruiting, OncoVerity, Inc. | Completed --> Active, not recruiting
    Enrollment closed
    |
    azacitidine • cusatuzumab (ARGX-110)
    10d
    OV-AML-1231: A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy (clinicaltrials.gov)
    P2, N=120, Recruiting, OncoVerity, Inc. | Active, not recruiting --> Recruiting
    Enrollment open
    |
    CD4 (CD4 Molecule)
    |
    Venclexta (venetoclax) • azacitidine • cusatuzumab (ARGX-110)
    2ms
    OV-AML-1231: A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy (clinicaltrials.gov)
    P2, N=120, Active, not recruiting, OncoVerity, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    CD4 (CD4 Molecule)
    |
    Venclexta (venetoclax) • azacitidine • cusatuzumab (ARGX-110)
    2ms
    CD70/CD27 signaling promotes the pathogenesis of multiple myeloma and represents a promising therapeutic target. (PubMed, Leukemia)
    Furthermore, the ADCC-enhanced anti-CD70 antibody, cusatuzumab, demonstrated high efficacy in treating myeloma in xenotransplantation models. Collectively, these findings underscore the critical role of CD70/CD27 signaling in activating MAPK/ERK and Wnt pathways essential for MM progression. Targeting CD70 with blocking or ADCC-enhanced antibodies represents a promising therapeutic strategy, particularly for advanced MM stages characterized by high CD70 expression.
    Journal • IO biomarker
    |
    CD70 (CD70 Molecule) • CD27 (CD27 Molecule)
    |
    cusatuzumab (ARGX-110)
    2ms
    CULMINATE: A Study of Cusatuzumab Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive Chemotherapy (clinicaltrials.gov)
    P2, N=103, Completed, OncoVerity, Inc. | Active, not recruiting --> Completed
    Trial completion
    |
    azacitidine • cusatuzumab (ARGX-110)
    9ms
    CULMINATE: A Study of Cusatuzumab Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive Chemotherapy (clinicaltrials.gov)
    P2, N=103, Active, not recruiting, OncoVerity, Inc. | Trial completion date: Aug 2025 --> May 2026
    Trial completion date
    |
    azacitidine • cusatuzumab (ARGX-110)
    1year
    ELEVATE: Cusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=61, Active, not recruiting, OncoVerity, Inc. | Trial completion date: May 2025 --> May 2026 | Trial primary completion date: May 2025 --> May 2026
    Trial completion date • Trial primary completion date
    |
    Venclexta (venetoclax) • azacitidine • cusatuzumab (ARGX-110)
    1year
    CULMINATE: A Study of Cusatuzumab Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive Chemotherapy (clinicaltrials.gov)
    P2, N=103, Active, not recruiting, OncoVerity, Inc. | Trial completion date: Aug 2024 --> Aug 2025
    Trial completion date
    |
    azacitidine • cusatuzumab (ARGX-110)
    almost2years
    CULMINATE: A Study of Cusatuzumab Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive Chemotherapy (clinicaltrials.gov)
    P2, N=103, Active, not recruiting, OncoVerity, Inc. | Trial completion date: Aug 2023 --> Aug 2024
    Trial completion date
    |
    azacitidine • cusatuzumab (ARGX-110)
    almost2years
    A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy (clinicaltrials.gov)
    P2, N=120, Recruiting, OncoVerity, Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Venclexta (venetoclax) • azacitidine • cusatuzumab (ARGX-110)
    almost2years
    ELEVATE: Cusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=61, Active, not recruiting, OncoVerity, Inc. | Phase classification: P1b --> P1 | Trial completion date: May 2024 --> May 2025 | Trial primary completion date: May 2024 --> May 2025
    Phase classification • Trial completion date • Trial primary completion date • Combination therapy
    |
    Venclexta (venetoclax) • azacitidine • cusatuzumab (ARGX-110)
    2years
    A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy (clinicaltrials.gov)
    P2, N=120, Not yet recruiting, OncoVerity, Inc.
    New P2 trial
    |
    Venclexta (venetoclax) • azacitidine • cusatuzumab (ARGX-110)